文章名稱引用次數

• Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population40
• Opioid medication discontinuation and risk of adverse opioid-related health care events23
• Telemedicine-delivered treatment interventions for substance use disorders: A systematic review23
• Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees19
• Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007-201418
• Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States17
• Developing an opioid use disorder treatment cascade: A review of quality measures16
• Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone16
• Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review15
• Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap12